Drugs Manufacturer from Hyderabad on overdrive
Optimus Pharma gets DCGI nod for conducting Phase III Clinical Trials for Molnupiravir on patients with mild and moderate COVID-19 infection
Hyderabad (Telangana) [India], May 19: Optimus Pharma on Tuesday received DCGI nod for conducting Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild and Moderate Covid-19 symptoms. With a severe shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.
Optimus pharma said having internally developed the active pharmaceutical ingredient (API) and the formulations for the product, it had filed for clinical trials with the DCGI. The regulator gave a nod for conducting the trial on mild and moderate patients on May 18 2021.
As per the clinical trial, protocols approved, a total of 2500 subjects in both mild and moderate COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with standard supportive care or standalone standard supportive care. The treatment duration is a maximum of 05 days and the total study duration will be a maximum for 29 days from randomisation, the release said.
“Optimus is all geared to immediately begin clinical trials on Molnupiravir on COVID-19 patients in India. The clinical trial will let us know the efficacy of this molecule on COVID-19 patients,” Chairman & Managing Director – Dr. D Srinivas Reddy said.
In the previous press release, the company stated that Molnupiravir demonstrated highly promising results in reducing viral load to 0.0% in merely 5 days of treatment duration. Based on completed phase 2 part clinical studies, the proposed dosage is 800mg twice daily which significantly reduces viral culture in infected patients not progressing into ARDS.
Optimus Pharma is one of the largest manufacturers of the highly successful SARS-CoV-2 antiviral drug without compromising on quality as is the case with Favipiravir (sold under the brand – FAVICOVID). The company aims to do the same with Molnupiravir to cater to the rising demand for Anti-Viral drugs against SARS-CoV-2 in the Indian market.
With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.
order forcan pill ampicillin pills buy cipro 1000mg generic
uroxatral canada heartburn medication over the counter best otc heartburn med
strongest sleeping pills for adults common medications causing hair loss best diet pills from mexico
buy femara 2.5mg abilify 30mg cost abilify us
get prescribe smoking cessation quit smoking aids australia buy prescription painkillers online
medroxyprogesterone price buy praziquantel sale buy hydrochlorothiazide generic
buying herpes medication online latest treatment for diabetics new drugs approved 2023
fungus clear now vitality health tablets for nail fungal infection what blood pressure medication has the least side effects
cymbalta 20mg us buy glucotrol 10mg without prescription buy provigil 200mg generic
duodenal ulcer diagnostic tests types of vasodilator drugs bacterial infection in bladder women
phenergan cost home remedies for ed erectile dysfunction stromectol for sale
emergency contraception where to buy online birth control prescription canada hims reviews and complaints
order deltasone generic how to buy isotretinoin amoxicillin 250mg over the counter
over the counter heartburn remedies hydrochloric acid supplements for digestion anti fart medication
buy azithromycin sale buy omnacortil brand gabapentin 100mg
ursodiol pills oral zyrtec zyrtec 10mg oral